TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) × CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY

<u>Niels W.C.J. van de Donk</u>¹, Amrita Y. Krishnan², Albert Oriol³, Jesus G. Berdeja⁴, Paula Rodríguez-Otero⁵, Elham Askari⁶, Maria-Victoria Mateos⁷, Monique C. Minnema⁸, Luciano J. Costa⁹, Raluca Verona¹⁰, Suzette Girgis¹⁰, Thomas Prior¹⁰, Brandi W. Hilder¹⁰, Jeffery Scott Russell¹⁰, Jenna D. Goldberg¹¹, Ajai Chari¹²

¹Amsterdam University Medical Center, VU University Medical Center, Amsterdam, Netherlands; ²City of Hope Comprehensive Cancer Center, Duarte, CA, USA; ³Institut Català d'Oncologia and Institut Josep Carreras Hospital Germans Trias i Pujol, Barcelona, Spain; ⁴Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ⁵Clínica Universidad de Navarra, Navarra, Spain; ⁶Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; ⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain; ⁸University Medical Center Utrecht, Utrecht, Netherlands; ⁹University of Alabama at Birmingham, Birmingham, AL, USA; ¹⁰Janssen R&D, Spring House, PA, USA; ¹¹Janssen R&D, Raritan, NJ, USA; ¹²Mount Sinai School of Medicine, New York, NY, USA

Previously presented at the American Society of Clinical Oncology Annual Meeting, June 4-8, 2021

Additional information can be viewed by accessing this link: <u>https://oncologysciencehub.com/IMW2021/talquetamab/vandedonk</u> Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the authors of this poster



Disclosures of Commercial Support

Niels W.C.J. van de Donk

Research Support: Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, and BMS

Advisory Board: Janssen Pharmaceuticals, AMGEN, Celgene, Adaptive, BMS, Takeda, Roche, Novartis, Bayer, and Servier.






TALQUETAMAB GPRC5D × CD3 Bispecific Antibody

- GPRC5D is a highly expressed receptor in MM, with limited expression in healthy human tissue¹⁻²
- Talquetamab is a first-in-class antibody that binds to CD3 and GPRC5D to redirect T cells to kill MM cells²⁻³
- In the ongoing, phase 1, first-in-human study of talquetamab in patients with RRMM, the RP2D was identified as a QW SC dose of 400 µg/kg^a (MonumenTAL-1; NCT03399799)⁴
- Here we present updated results of safety and efficacy of talquetamab at the RP2D, with additional patients and longer follow-up

^a400 μg/kg was selected as final dosing concentration in phase 2 for operational convenience; In phase 1, 405 μg/kg was the RP2D. GPRC5D, G protein-coupled receptor family C group 5 member D; IFN, interferon; IL, interleukin; MM, multiple myeloma; QW, once weekly; RP2D, recommended phase 2 dose; RRMM, relapsed/refractory multiple myeloma; SC, subcutaneous; TNF, tumor necrosis factor. 1. Smith EL, et al. *Sci Transl Med* 2019;11:eaau7746. 2. Pillarisetti K, et al. *Blood* 2020;135:1232-43. 3. Verkleij CPM, et al. *Blood Adv*. 2021; 5:2196-2215. 4. Chari A, et al. 62nd ASH Annual Meeting and Exposition 2020, Abstract 290.








TALQUETAMAB MonumenTAL-1 Study Design

Key Objectives

- Part 1: Identify RP2D
- Part 2: Safety and tolerability at RP2D
- Antitumor activity, pharmacokinetics, pharmacodynamics

- Adults with measurable MM
- ANC ≥1.0×10⁹/L



The data cut-off date for these analyses was April 18, 2021

^aGlucocorticoid, antihistamine, and antipyretic; ^b1-3 step-up doses given within 1 week before a full dose; ^cStep-up doses of 10 and 60 µg/kg. ANC, absolute neutrophil count; BCMA, B-cell maturation antigen; IV, intravenous; MM, multiple myeloma; MTD, maximum tolerated dose; QW, every week; RP2D, recommended phase 2 dose; RR, relapsed/refractory; SC, subcutaneous.









TALQUETAMAB Patient Demographics and Disease Characteristics

Characteristic	SC Total n=82	RP2D (405 µg/kg SC QW)ª n=30	Characteristic	SC Total n=82	RP2D (405 µg/kg SC QW)ª n=30
Age, years, median (range)	63.0 (42–80)	61.5 (46–80)	Prior lines of therapy, n, median (range)	6.0 (2–17)	6.0 (2–14)
Age ≥70 years, n (%)	22 (27)	7 (23)	Exposure status, n (%)		
Sex, n (%)			Prior BCMA therapy ^e	20 (24)	8 (27)
Male	47 (57)	19 (63)	Triple-class ^f	81 (99)	30 (100)
Female	35 (43)	11 (37)	Penta-drug ^g	64 (78)	24 (80)
		11 (07)	Refractory status, n (%)		
Years since diagnosis, median (range)	5.9 (1–20)	5.6 (2–20) Pi ^h		69 (84)	25 (83)
Extramedullary plasmacytomas ≥1, n (%) ^b	27 (33)	10 (33)	Carfilzomib	54 (66)	19 (63)
Bone marrow plasma cells ≥60%, n (%) ^c	13 (17)	6 (21)	IMiD ⁱ	76 (93)	28 (93)
ISS stage, n (%) ^d			Pomalidomide	67 (82)	26 (87)
	26 (32)	12 (40)	Anti-CD38 mAb ^j	77 (94)	30 (100)
			BCMA ^e	14 (17)	5 (16)
	36 (44)	13 (43)	Triple-class ^f	62 (76)	23 (77)
	13 (16)	3 (10)	Penta-drug ^g	23 (28)	6 (20)
Prior transplantation, n (%)	71 (87)	27 (90)	To last line of therapy	69 (84)	26 (87)

^aStep-up doses of 10 µg/kg and 60 µg/kg; ^bSoft-tissue component of a bone-based plasmacytoma not included; ^cPercentages calculated from n=76 for SC total and n=29 at RP2D; ^dPercentages calculated from n=66 for SC total and n=27 at RP2D; ^eBCMA CAR-T therapy or BCMA non-CAR-T therapy; ^f≥1 PI, ≥1 IMiD, and 1 anti-CD38 mAb; ^g≥2 PI, ≥2 IMiD, and 1 anti-CD38 mAb; ^hBortezomib, carfilzomib, and/or ixazomib; ⁱThalidomide, lenalidomide, and/or pomalidomide; ^jDaratumumab and/or isatuximab. BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T cell; IMiD, immunomodulatory drug; ISS, International Staging System; mAb, monoclonal antibody; PI, proteasome inhibitor; QW, weekly; RP2D, recommended phase 2 dose; SC, subcutaneous.









TALQUETAMAB Safety Profile

AE (>200/ of total SC)		Fotal 82	RP2D (405 μg/kg SC QW) ^a n=30	
AE (≥20% of total SC), n (%)	Any grade	Grade 3/4	Any Grade	Grade 3/4
Hematologic				
Neutropenia	47 (57)	40 (49)	20 (67)	18 (60)
Anemia	37 (45)	23 (28)	17 (57)	8 (27)
Thrombocytopenia	23 (28)	15 (18)	10 (33)	6 (20)
Leukopenia	21 (26)	16 (20)	11 (37)	8 (27)
Lymphopenia	19 (23)	19 (23)	9 (30)	9 (30)
Nonhematologic				
CRS	55 (67)	1 (1)	22 (73)	1 (2)
Dysgeusia	38 (46)	NA	18 (60)	NA
Fatigue	26 (32)	0	9 (30)	0
Pyrexia	23 (28)	1 (1)	7 (23)	1 (2)
Dry mouth	22 (27)	0	8 (27)	0
Dysphagia	21 (26)	0	11 (37)	0
Headache	19 (23)	1 (1)	7 (23)	0
Diarrhea	18 (22)	0	7 (23)	0
Nausea	18 (22)	0	7 (23)	0

^aStep-up doses of 10 µg/kg and 60 µg/kg; ^bIncludes skin exfoliation, pruritis, rash, and nail disorders; ^cIncludes nail disorders, onychomadesis, and nail dystrophy. AE, adverse event, CRS, cytokine release syndrome; DLT, dose-limiting toxicity; NA, not applicable; RP2D, recommended phase 2 dose; SC, subcutaneous.



- Talquetamab has a tolerable safety profile at the RP2D of 405 $\mu g/kg$ SC
 - No DLTs at the RP2D
 - Cytopenias mostly confined to step-up doses and cycles 1/2
 - Neutropenias generally resolved within a week and were limited to cycles 1/2
- Infections in 37% of SC and RP2D patients (grade 3/4: 9% for SC total, 3% for RP2D)
- Neurotoxicities (all grade 1/2) in 4 patients with SC dosing; 2 patients (7%) at RP2D
- Injection-site reactions in 17% of SC patients (including RP2D) were mild and manageable (all grade 1/2)
- Skin-related AEs^b in 67% of SC patients; 77% at RP2D (majority grade 1/2)
 - Nail disorders^c in 21% of patients; 27% at RP2D
- No deaths due to AEs at the RP2D




TALQUETAMAB Cytokine Release Syndrome

Parameter	SC Total n=82	RP2D (405 µg/kg SC QW)ª n=30	
Patients with CRS, n (%)	55 (67)	22 (73)	
Time to onset, days, ^b median (range)	2 (1–22)	2 (1–22)	
Duration, days, median (range)	2 (1–7)	2 (1–3)	
Supportive measures, n (%) ^c	55 (67)	22 (73)	
Tocilizumab ^d	43 (52)	18 (60)	
Steroids	5 (6)	1 (3)	• (
Low-flow oxygen by nasal cannula	6 (7)	1 (3)	• / E
Vasopressor	2 (2)	1 (3)	_

^aStep-up doses of 10 µg/kg and 60 µg/kg; ^bRelative to the most recent dose; ^cA patient could receive >1 supportive therapy; ^dTocilizumab was allowed for all CRS events; ^eGraded according to Lee et al. *Blood* 2014;124:188. CRS, cytokine release syndrome; QW, weekly; RP2D, recommended phase 2 dose; SC, subcutaneous.

Presented By: Niels W.C.J. van de Donk




CRS was generally confined to step-up and first full doses

Across all SC cohorts, CRS was limited to grade 1/2 in all patients, with the exception of 1 patient with grade 3 CRS

Majority of patients only had 1 dose of tocilizumab as a supportive measure for CRS



































TALQUETAMAB **Overall Response Rate**




^aInvestigator assessment of evaluable patients who had ≥1 dose of talquetamab and ≥1 postbaseline disease evaluation per 2011 International Myeloma Working Group response criteria; includes unconfirmed response. CR, complete response; IV, intravenous; MRD, minimal residual disease; ORR, overall response rate; PR, partial response; QW, weekly; RP2D, recommended phase 2 dose; SC, subcutaneous; sCR, stringent complete response; VGPR, very good partial response.




- The RP2D of 405 µg/kg SC QW has been administered to 30 patients with a median follow-up of 6.3 months (range: 1.4–12.0) for responders
- At the RP2D:
- 70.0% ORR (21/30)
- Median time to first confirmed response was 1 month (range: 0.2–3.8)
- 65.2% (15/23) of triple-refractory patients responded
- 83.3% (5/6) of penta-refractory patients responded
- Of 6 evaluable patients across IV and SC cohorts, 4 had MRDnegative CR/sCR at 10⁻⁶, including 1 patient in RP2D cohort
- MRD negativity was sustained 7 months post CR in 1 evaluable patient












TALQUETAMAB **Duration of Response**




CR, complete response; D/C, discontinued; IV, intravenous; MR, minimal response; PD, progressive disease; PR, partial response; QW, weekly; RP2D, recommended phase 2 dose; SC, subcutaneous; sCR, stringent complete response; SD, stable disease; TR, triple-class refractory; VGPR, very good partial response.



- Responses were durable and deepened over time
- At the RP2D of 405 μ g/kg SC QW:
 - Median duration of response was not reached
 - 17/21 responders (81%) were continuing on treatment, after median follow-up of 6.3 months (range: 1.4–12.2)
- Data from IV cohorts (not shown) were more mature
 - Even at subtherapeutic doses, responses are ongoing at 22+ months in patients with longer follow-up










TALQUETAMAB **Pharmacokinetics**

Pharmacokinetic Profile Following the First 405 µg/kg SC Dose



^aEC90 was experimentally determined from an ex vivo cytotoxicity assay EC₉₀, 90% effective concentration; QW, weekly; RP2D, recommended phase 2 dose; SC, subcutaneous.




- 405 µg/kg SC has low peak/trough ratio and maintains exposure over the maximum EC₉₀^a
- Immunogenicity lacksquare
 - 6 of 50 patients (12%) treated with talquetamab SC had antidrug antibodies, generally of low titer
 - Antidrug antibodies did not appear to impact safety, pharmacokinetics, or efficacy



TALQUETAMAB Pharmacodynamics

Induction of PD-1–Positive T Cells With SC Dosing



^aFold change of total T cells that were PD-1 positive; ^bStep-up doses of 10 µg/kg and 60 µg/kg. IL, interleukin; IL-2Rα, interleukin-2 receptor subunit alpha; PD-1, programmed cell death protein-1; RP2D, recommended phase 2 dose; SC, subcutaneous.



- Post talquetamab administration, PD- \bullet 1-positive T cells were induced in the periphery, indicative of T cell activation
 - Consistent induction of PD-1+ T cells is observed in RP2D cohorts
- Consistent induction of cytokines (ie, IL-10, IL-6, IL-2Rα) is observed at doses >45 µg/kg SC



TALQUETAMAB Conclusions

- Talguetamab is an off-the-shelf T-cell redirecting, GPRC5D targeting agent that requires limited steroid use and has a manageable safety profile at a dose of 405 µg/kg SC QW
- Additional patients and longer follow-up support the RP2D
 - A high response rate (70% ORR) was observed
 - High response rate was maintained in triple-refractory and penta-refractory patients (65% and 84%, respectively)
 - Responses were durable and continued to deepen over time
 - Pharmacokinetic and pharmacodynamic data continue to support the RP2D
- Talquetamab showed encouraging efficacy in heavily pretreated patients with RRMM
 - A phase 2 expansion study of talquetamab at the RP2D^a is in progress (NCT04634552)

GPCR5D, G protein-coupled receptor family C group 5 member D; ORR, overall response rate; RP2D, recommended phase 2 dose; RRMM, relapsed/refractory multiple myeloma; SC, subcutaneous; QW, weekly.





^a400 μg/kg selected as final dosing concentration in phase 2 for operational convenience.

Acknowledgments

- We thank the patients who are participated in this study and their caregivers, the physicians and nurses who took care of them, the staff at study sites and the staff involved in data collection and analyses.
- This study was funded by Janssen Research & Development, LLC





